Vancomycin (oral)

Vancomycin (oral)

Clinical data
Pregnancy category	B2 (Au), B (U.S.)
Routes of administration	IV, oral
ATC code	A07AA09 (WHO) J01XA01 (WHO)
Legal status
Legal status	S4 (Au), POM (UK), ℞-only (U.S.)
Pharmacokinetic data
Bioavailability	Negligible (oral)
Metabolism	Excreted unchanged
Elimination half-life	4–11 hours (adults) 6-10 days (adults, impaired renal function)
Excretion	Renal
Identifiers
IUPAC name unable to be assigned
CAS Number	1404-90-6
PubChem CID	14969
DrugBank	APRD01287
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C66H75Cl2N9O24
Molar mass	1449.3 g.mol-1

WikiDoc Resources for Vancomycin (oral)
Articles
Most recent articles on Vancomycin (oral) Most cited articles on Vancomycin (oral) Review articles on Vancomycin (oral) Articles on Vancomycin (oral) in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Vancomycin (oral) Images of Vancomycin (oral) Photos of Vancomycin (oral) Podcasts & MP3s on Vancomycin (oral) Videos on Vancomycin (oral)
Evidence Based Medicine
Cochrane Collaboration on Vancomycin (oral) Bandolier on Vancomycin (oral) TRIP on Vancomycin (oral)
Clinical Trials
Ongoing Trials on Vancomycin (oral) at Clinical Trials.gov Trial results on Vancomycin (oral) Clinical Trials on Vancomycin (oral) at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Vancomycin (oral) NICE Guidance on Vancomycin (oral) NHS PRODIGY Guidance FDA on Vancomycin (oral) CDC on Vancomycin (oral)
Books
Books on Vancomycin (oral)
News
Vancomycin (oral) in the news Be alerted to news on Vancomycin (oral) News trends on Vancomycin (oral)
Commentary
Blogs on Vancomycin (oral)
Definitions
Definitions of Vancomycin (oral)
Patient Resources / Community
Patient resources on Vancomycin (oral) Discussion groups on Vancomycin (oral) Patient Handouts on Vancomycin (oral) Directions to Hospitals Treating Vancomycin (oral) Risk calculators and risk factors for Vancomycin (oral)
Healthcare Provider Resources
Symptoms of Vancomycin (oral) Causes & Risk Factors for Vancomycin (oral) Diagnostic studies for Vancomycin (oral) Treatment of Vancomycin (oral)
Continuing Medical Education (CME)
CME Programs on Vancomycin (oral)
International
Vancomycin (oral) en Espanol Vancomycin (oral) en Francais
Business
Vancomycin (oral) in the Marketplace Patents on Vancomycin (oral)
Experimental / Informatics
List of terms related to Vancomycin (oral)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Crystal structure of a short peptide L-Lys-D-Ala-D-Ala (bacterial cell wall precursor, in green) bound to vancomycin (blue) through hydrogen bonds. Reported by Knox and Pratt in Antimicrob. Agents. Chemother., 1990 1342-1347

Vancomycin (INN) (Template:PronEng) is a glycopeptide antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. It has traditionally been reserved as a drug of "last resort", used only after treatment with other antibiotics had failed, although the emergence of vancomycin-resistant organisms means that it is increasingly being displaced from this role by linezolid and the carbapenems.

History

Vancomycin was first isolated by EC Kornfeld (working at Eli Lilly) from a soil sample collected from the interior jungles of Borneo by a missionary. The organism that produced it was eventually named Amycolatopsis orientalis. The original indication for vancomycin was for the treatment of penicillin-resistant Staphylococcus aureus.

The compound was initially labelled compound 05865, but was eventually given the generic name, vancomycin (derived from the word "vanquished"). One advantage that was quickly apparent was that staphylococci did not develop significant resistance despite serial passage in culture media containing vancomycin. The rapid development of penicillin-resistance by staphylococci led to the compound being fast-tracked for approval by the FDA in 1958. Eli Lilly first marketed vancomycin hydrochloride under the trade name Vancocin.

Vancomycin never became first line treatment for Staphylococcus aureus for several reasons:

1. The drug must be given intravenously, because it is not absorbed orally.
2. β-lactamase-resistant semi-synthetic penicillins such as methicillin (and its successors, nafcillin and cloxacillin) were subsequently developed.
3. Early trials using early impure forms of vancomycin ("Mississippi mud") which were found to be toxic to the ears and to the kidneys; these findings led to vancomycin being relegated to the position of a drug of last resort.

In 2004, Eli Lilly licensed Vancocin to ViroPharma in the U.S., Flynn Pharma in the UK and Aspen Pharmacare in Australia. The patent expired in the early 1980s and generic versions of the drug are also available under various trade names.

Pharmacology and chemistry

It is a branched tricyclic glycosylated nonribosomal peptide produced by the fermentation of the Actinobacteria species Amycolatopsis orientalis (formerly designated Nocardia orientalis).

Vancomycin acts by inhibiting proper cell wall synthesis in Gram-positive bacteria. The mechanism inhibited, and various factors related to entering the outer membrane of Gram-negative organisms mean that vancomycin is not active against Gram-negative bacteria (except some non-gonococcal species of Neisseria).

Specifically, vancomycin prevents incorporation of N-acetylmuramic acid (NAM)- and N-acetylglucosamine (NAG)-peptide subunits into the peptidoglycan matrix; which forms the major structural component of Gram-positive cell walls.

The large hydrophilic molecule is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides. Normally this is a five-point interaction. This binding of vancomycin to the D-Ala-D-Ala prevents the incorporation of the NAM/NAG-peptide subunits into the peptidoglycan matrix.

Vancomycin exhibits atropisomerism — it has two chemically distinct rotamers owing to the rotational restriction of the chlorotyrosine residue (on the right hand side of the figure). The form present in the drug is the thermodynamically more stable conformer, and, importantly, has more potent activity.

Vancomycin can be given orally, but this method is very expensive. It may also be used in treatment for clostridium difficile.

Clinical use

Indications

Vancomycin is indicated for the treatment of serious, life-threatening infections by Gram-positive bacteria which are unresponsive to other less toxic antibiotics. In particular, vancomycin should not be used to treat methicillin-sensitive Staphylococcus aureus because it is inferior to penicillins such as nafcillin.

The increasing emergence of vancomycin-resistant enterococci has resulted in the development of guidelines for use by the Centers for Disease Control (CDC) Hospital Infection Control Practices Advisory Committee. These guidelines restrict use of vancomycin to the following indications:

• treatment of serious infections caused by susceptible organisms resistant to penicillins (methicillin-resistant Staphylococcus aureus and multi-resistant Staphylococcus epidermidis (MRSE)) or in individuals with serious allergy to penicillins
• pseudomembranous colitis (relapse or unresponsive to metronidazole treatment)
• For treatment of infections caused by gram-positive microorganisms in patients who have serious allergies to beta-lactam antimicrobials. (http://wonder.cdc.gov/wonder/prevguid/m0039349/m0039349.asp)
• antibacterial prophylaxis for endocarditis following certain procedures in penicillin-hypersensitive individuals at high risk
• surgical prophylaxis for major procedures involving implantation of prostheses in institutions with a high rate of MRSA or MRSE

Adverse effects

Common adverse drug reactions (≥1% of patients) associated with IV vancomycin include: local pain, which may be severe and/or thrombophlebitis.

Damage to the kidneys and to the hearing were a side effect of the early impure versions of vancomycin, and these were prominent in the clinical trials conducted in the mid-1950s. Later trials using purer forms of vancomycin found that nephrotoxicity is an infrequent adverse effect (0.1–1% of patients), but that this is accentuated in the presence of aminoglycosides.

Rare adverse effects (<0.1% of patients) include: anaphylaxis, toxic epidermal necrolysis, erythema multiforme, red man syndrome (see below), superinfection, thrombocytopenia, neutropenia, leucopenia, tinnitus, dizziness and/or ototoxicity (see below).

Lately it has been emphasized that vancomycin can induce platelet-reactive antibodies in the patient, leading to severe thrombocytopenia and bleeding with florid petechial hemorrhages, ecchymoses, and wet purpura.

Dosing considerations

Intravenous vs oral administration

Vancomycin needs to be given intravenously (IV) for systemic therapy since it does not cross through the intestinal lining. It is a large hydrophilic molecule which partitions poorly across the gastrointestinal mucosa. The only indication for oral vancomycin therapy is in the treatment of pseudomembranous colitis, where it must be given orally to reach the site of infection in the colon. Inhaled vancomycin has also been used (off-label), via nebulizer, for treatment of various infections of the upper and lower respiratory tract.

Red man syndrome

• Vancomycin must be administered in a dilute solution slowly, over at least 60 minutes (maximum rate of 10 mg/minute for doses >500 mg).
• This is due to the high incidence of pain and thrombophlebitis and to avoid an infusion reaction known as the red man syndrome or red neck syndrome.
• This syndrome, usually appearing within 4–10 minutes after the commencement or soon after the completion of an infusion, is characterised by flushing and/or and an erythematous rash that affects the face, neck and upper torso.
• Less frequently, hypotension and angioedema may also occur.
• Symptoms may be treated with antihistamines, including diphenhydramine.

Vancomycin target troughs

While treating a patient with vancomycin a target trough of at least 10 mcg/mL should be achieved. This is important due to the following:

• Decreases the risk of microbes with elevated vancomycin minimum inhibitory concentrations (MICs).
• Microbes with elevated MICs towards vancomycin have shown decreased susceptibility to other antimicrobials agents such as daptomycin. Thus, maintaining a trough of atleast 10 mcg/mL helps in avoiding development of resistance to other microbes too.

Therapeutic drug monitoring

Vancomycin activity is considered to be time-dependent – that is, antimicrobial activity depends on the duration that the drug level exceeds the minimum inhibitory concentration (MIC) of the target organism. Thus, peak levels have not been shown to correlate with efficacy or toxicity – indeed concentration monitoring is unnecessary in most cases. Circumstances where therapeutic drug monitoring (TDM) is warranted include: patients receiving concomitant aminoglycoside therapy, patients with (potentially) altered pharmacokinetic parameters, patients on haemodialysis, during high dose or prolonged treatment, and patients with impaired renal function. In such cases, trough concentrations are measured.

Toxicity

Vancomycin has traditionally been considered a nephrotoxic and ototoxic drug, based on observations by early investigators of elevated serum levels in renally impaired patients who had experienced ototoxicity, and subsequently through case reports in the medical literature. However, as the use of vancomycin increased with the spread of MRSA beginning in the seventies, it was recognised that the previously reported rates of toxicity were not being observed. This was attributed to the removal of the impurities present in the earlier formulation of the drug, although those impurities were not specifically tested for toxicity.

Nephrotoxicity

Subsequent reviews of accumulated case reports of vancomycin-related nephrotoxicity found that many of the patients had also received other known nephrotoxins, particularly aminoglycosides. Most of the rest had other confounding factors, or insufficient data regarding the possibility of such, that prohibited the clear association of vancomycin with the observed renal dysfunction.

In 1994, Cantu and colleagues found that the use of vancomycin monotherapy was clearly documented in only three of 82 available cases in the literature. Prospective and retrospective studies attempting to evaluate the incidence of vancomycin-related nephrotoxicity have largely been methodologically flawed and have produced variable results. The most methodologically sound investigations indicate that the actual incidence of vancomycin-induced nephrotoxicity is around 5–7%. To put this into context, similar rates of renal dysfunction have been reported for cefamandole and benzylpenicillin, two reputedly non-nephrotoxic antibiotics.

Additionally, evidence to relate nephrotoxicity to vancomycin serum levels is inconsistent. Some studies have indicated an increased rate of nephrotoxicity when trough levels exceed 10 µg/mL, but others have not reproduced these results. Nephrotoxicity has also been observed with concentrations within the "therapeutic" range as well. Essentially, the reputation of vancomycin as a nephrotoxin is over-stated, and it has not been demonstrated that maintaining vancomycin serum levels within certain ranges will prevent its nephrotoxic effects, when they do occur.

Ototoxicity

Attempts to establish rates of vancomycin-induced ototoxicity are even more difficult due to the scarcity of quality evidence. The current consensus is that clearly related cases of vancomycin ototoxicity are rare. The association between vancomycin serum levels and ototoxicity is also uncertain. While cases of ototoxicity have been reported in patients whose vancomycin serum level exceeded 80 µg/mL, cases have been reported in patients with therapeutic levels as well. Thus, it also remains unproven that therapeutic drug monitoring of vancomycin for the purpose of maintaining "therapeutic" levels will prevent ototoxicity.

Interactions with other nephrotoxins

Another area of controversy and uncertainty concerns the question of whether, and if so, to what extent, vancomycin increases the toxicity of other nephrotoxins. Clinical studies have yielded variable results, but animal models indicate that there probably is some increased nephrotoxic effect when vancomycin is added to nephrotoxins such as aminoglycosides. However, a dose- or serum level-effect relationship has not been established.

Antibiotic resistance

Intrinsic resistance

There are a few gram-positive bacteria that are intrinsically resistant to vancomycin: these are Leuconostoc and Pediococcus species, but these organisms are rare causes of disease in humans. Most Lactobacillus species are also intrinsically resistant to vancomycin (the exception is the finding of a few strains (but not all) of L. acidophilus).

Most gram-negative bacteria are intrinsically resistant to vancomycin because of their outer membrane is impermeable to large glycopeptide molecules (with the exception of some non-gonococcal Neisseria species).

Acquired resistance

Acquired microbial resistance to vancomycin is a growing problem, particularly within health care facilities such as hospitals. With vancomycin being the last-line antibiotic for serious Gram-positive infections there is the growing prospect that resistance will result in a return to the days when fatal bacterial infections were common.

Vancomycin-resistant enterococcus (VRE) emerged in 1987. Vancomycin resistance emerged in more common pathogenic organisms during the 1990s and 2000s, including vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-resistant Staphylococcus aureus (VRSA), and vancomycin-resistant Clostridium difficile. There is some suspicion that agricultural use of avoparcin, another similar glycopeptide antibiotic, has contributed to the emergence of vancomycin-resistant organisms.

One mechanism of resistance to vancomycin appears to be alteration to the terminal amino acid residues of the NAM/NAG-peptide subunits, normally D-alanyl-D-alanine, which vancomycin binds to. Variations such as D-alanyl-D-lactate and D-alanyl-D-serine result in only a 4-point hydrogen bonding interaction being possible between vancomycin and the peptide. This loss of just one point of interaction results in a 1000-fold decrease in affinity.

In Enterococci this modification appears to be due to the expression of an enzyme which alters the terminal residue. Three main resistance variants have been characterised to date among resistant Enterococcus faecium and E. faecalis populations.

• VanA - resistance to vancomycin and teicoplanin, inducible on exposure to these agents
• VanB - lower level resistance, inducible by vancomycin but strains may remain susceptible to teicoplanin
• VanC - least clinically important, resistance only to vancomycin, constitutive resistance

The development and use of novel antibiotics such as linezolid and daptomycin is expected to delay, but not halt, the emergence of bacteria resistant to all available antibiotics.

See also

• Drug resistance
• Antibiotic resistance
• Methicillin-resistant Staphylococcus aureus
• Vancomycin-resistant Staphylococcus aureus
• Vancomycin-resistant enterococcus

External links

• Vancomycin information site and forum

ar:فانكومايسن de:Vancomycin hr:Vankomicin nl:Vancomycine no:Vancomycin fi:Vankomysiini sv:Vankomycin